VEGF

[Akeso, Inc. (PR Newswire, Inc.)] Akeso, Inc. announced that Ligufalimab and Ivonescimab have obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate a Phase II clinical trial with chemotherapy as first-line therapy for unresectable locally advanced or metastatic triple negative breast cancer.

[Journal of Proteomics] The authors studied the proteome profiled of canine native and decellularized placenta to characterize the proteome related to maintenance of a microenvironment and structure suitable for tissue engineering applications.

[Journal of Cellular Physiology] The authors examined the early effect of photobiomodulation (PBM) in pericytes from experimentally injured pulp tissue. In vitro, PBM induced VEGF upregulation, improved dental pulp cells proliferation and migration, and favored their mineralization potential.

[Cell Death Discovery] Investigators suggested that treatment with vascular endothelial growth factor receptor 2 (VEGFR2)-tyrosine kinase inhibitors upregulated ADRB2 expression in NSCLC cells.

[Brain] Scientists reported that VEGF signaling at the luminal side of the brain microvasculature played an integral role in the capillary stalling phenomenon of the APP/PS1 mouse model.

[Compass Therapeutics, Inc.] Compass Therapeutics, Inc. announced that the FDA has cleared its IND application for CTX-009, enabling the company to initiate a global Phase II clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers in the United States and South Korea.